Objective: To explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed or refractory peripheral T-cell lymphoma(PTCL).
Methods: The clinical data of 6 patients with relapsed or refractory PTCL undergoing allo-HSCT from Sep. 2014 to Sep. 2018 in the department of hematology, aerospace center hospital were retrospectively analyzed. Complications and disease-free survival after HSCT were observed.
Results: All the patients could well tolerate the conditioning regimen and acquired hematopoietic recon-struction. Following up till December 2018, with a median time of 11.5 months (1-51); acute GVHD developed in 2 cases and chronic GVHD developed in 5 cases, Among 6 cases one case died of viral pheumonia and the other 5 patients remained disease-free survival. The longest disease-free survival time has reached 51 months.
Conclusion: allo-HSCT is a safe and effective method for relapsed or refractory peripheral T-cell lymphoma, which can be chosen as salvage treatment method for patients with primary resistance. Optimization of the conditioning regimen may result in better efficacy of allo-HSCT.
题目: 异基因造血干细胞移植治疗复发难治性外周T细胞淋巴瘤的临床研究.
目的: 探讨异基因造血干细胞移植(allo-HSCT)治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性.
方法: 回顾分析2014年9月至2018年9月在航天中心医院血液科接受allo-HSCT治疗的6例复发/难治性外周T细胞淋巴瘤患者的临床资料，观察患者移植并发症和无病生存等情况.
结果: 6例患者均能耐受预处理方案，均获造血重建，随访至2018年12月，中位随访11.5 (1-51) 个月， 2例发生急性GVHD，5例发生慢性GVHD。6例中死亡1例(病毒性肺炎)，其余5例患者无病生存，最长无病生存时间已达51个月.
结论: allo-HSCT治疗复发/难治性外周T细胞淋巴瘤安全有效，对于原发耐药患者可作为挽救性治疗技术，预处理方案的优化可能会使allo-HSCT取得更佳的疗效.